EuroSciCon has moved the date of its meeting 'Proteomics: advances in biomarker discovery' to 23 November 2007, after learning that the original date clashed with other similar events
EuroSciCon says the new date will ensure that as many scientists as possible can be a part of this meeting.
Proteomics is an exciting area of research that holds promise for the future.
It is widely accepted that proteomics holds the potential to identify new diagnostic and or prognostic biomarkers, and drug targets for the development of new therapeutic approaches for fighting disease.
Proteomics, the large scale analysis of gene expression at the protein level incorporates structural, interaction and expression proteomics.
Using expression proteomics, the aim is to detect and identify all, or a subset, of the proteins in a given sample and find out which of these proteins are present, absent, or differentially expressed in a related sample subject to as specific variation.
For example, proteomics enables the identification of protein alterations responsible for the development and the pathological outcome of disease leading to the discovery of new protein markers, biomarkers, for diagnostic/prognostic purposes and of novel molecular targets for drug discovery.
A combination of two-dimensional gel electrophoresis and mass spectrometry are the most widely used tools in this area of proteomics, although many other technologies are also currently available and continually emerging.
''This meeting examines the use of proteomics in the identification of biomarkers using a variety of old, new and developing technologies'', meeting chair - Ayesha De Souza, St George's Hospital, London.
Other speakers include Ashley Martin (CRUK Institute for Cancer Studies, University of Birmingham), Robin Wait (Kennedy Institute of Rheumatology, Imperial College London), Mark Weeks (Institute of Cancer), Professor Robert Rees (Department of Life Sciences, Nottingham Trent University), Delmiro Fernandez-Reyes (National Institute for Medical Research, London), Lynn Cawkwell (University of Hull), Judit Nagy (Imperial College), and Malcolm Ward (Proteome Sciences)
